Gain Therapeutics (GANX) Net Equity Issued and Repurchased (2023 - 2026)

Gain Therapeutics' Net Equity Issued and Repurchased history runs 3 years deep, the most recent figure standing at $400000.0 for Q1 2026.

• In Q1 2026, Net Equity Issued and Repurchased fell 92.91% year-over-year to $400000.0; the TTM figure through Mar 2026 stood at $29.9 million (up 241.07% YoY), while the FY2025 annual figure was $18.8 million, up 506.45% from the prior year.
• Net Equity Issued and Repurchased for Q1 2026 stood at $400000.0, down from $13.6 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $13.6 million in Q4 2025, with the low at $157103.0 in Q3 2023.
• The 3-year median for Net Equity Issued and Repurchased is $2.2 million (2023), against an average of $4.4 million.
• Peak annual rise in Net Equity Issued and Repurchased reached 92.91% in 2026, while the deepest fall reached 92.91% in 2026.
• Gain Therapeutics' Net Equity Issued and Repurchased stood at $752767.0 in 2023, then surged by 1711.98% to $13.6 million in 2025, then sank by 97.07% to $400000.0 in 2026.
• Business Quant data shows GANX's Net Equity Issued and Repurchased at $400000.0 in Q1 2026, $13.6 million in Q4 2025, and $7.6 million in Q3 2025.